18-Nov-2026 17:02:03

PPLPHARMAAcquisition and merger

PPLPHARMA : TO ACQUIRE BALANCE 26% STAKE IN YAPAN BIO

• Administrative Committee of the Board approved exercise of the company's call option to buy the balance 26% equity stake in Yapan Bio from existing shareholders • Shareholding in Yapan is expected to rise from 74% to 100%, making it a wholly owned subsidiary • Final terms, including acquisition consideration and effective date of share transfer, are yet to be finalized • Yapan is a CDMO focused on process development, characterization and Phase I/II GMP manufacturing for vaccines and biologics • Definitive documentation and completion will be disclosed separately under Regulation 30

Piramal Pharma Ltd

Open attachment

← Back to feed